HomeComparePIRS vs BTI

PIRS vs BTI: Dividend Comparison 2026

PIRS yields 14.71% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PIRS wins by $14.8K in total portfolio value
10 years
PIRS
PIRS
● Live price
14.71%
Share price
$13.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.5K
Annual income
$3,650.55
Full PIRS calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — PIRS vs BTI

📍 PIRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIRSBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIRS + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIRS pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIRS
Annual income on $10K today (after 15% tax)
$1,250.00/yr
After 10yr DRIP, annual income (after tax)
$3,102.97/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, PIRS beats the other by $734.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIRS + BTI for your $10,000?

PIRS: 50%BTI: 50%
100% BTI50/50100% PIRS
Portfolio after 10yr
$45.1K
Annual income
$3,218.59/yr
Blended yield
7.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

PIRS
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-1.7
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIRS buys
0
BTI buys
0
No recent congressional trades found for PIRS or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIRSBTI
Forward yield14.71%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$52.5K$37.7K
Annual income after 10y$3,650.55$2,786.64
Total dividends collected$25.1K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: PIRS vs BTI ($10,000, DRIP)

YearPIRS PortfolioPIRS Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,171$1,470.59$11,299$598.92+$872.00PIRS
2$14,695$1,672.70$12,794$703.91+$1.9KPIRS
3$17,611$1,887.56$14,518$829.07+$3.1KPIRS
4$20,958$2,114.15$16,513$978.64+$4.4KPIRS
5$24,777$2,351.33$18,827$1,157.84+$6.0KPIRS
6$29,109$2,597.87$21,518$1,373.12+$7.6KPIRS
7$33,999$2,852.44$24,657$1,632.46+$9.3KPIRS
8$39,493$3,113.67$28,329$1,945.74+$11.2KPIRS
9$45,637$3,380.17$32,637$2,325.33+$13.0KPIRS
10$52,483$3,650.55$37,708$2,786.64+$14.8KPIRS

PIRS vs BTI: Complete Analysis 2026

PIRSStock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Full PIRS Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this PIRS vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIRS vs SCHDPIRS vs JEPIPIRS vs OPIRS vs KOPIRS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.